Cytos Biotechnology yesterday announced that their Phase IIb clinical study of CYT003 failed to meet its primary or secondary endpoints. The clinical trial tested patients with moderate to severe allergic asthma, and showed that the immune modulator did not achieve a statistically significant reduction of the Asthma Control Questionnaire (ACQ) score at week 12 in
click Xalkori” src=”http://i61.tinypic.com/kng1x.jpg” width=”204″ height=”126″ />Pfizer have announced positive late-stage clinical data from a phase III trial of Xalkori, in comparison to chemotherapy. Pfizer revealed that the clinical study met the primary objective of significantly prolonging progression-free survival in previously-untreated patients with anaplastic lymphoma kinase (ALK)-positive advanced non-squamous non-small cell lung cancer (NSCLC), when compared
>Amgen yesterday announced further positive clinical data for their novel cholesterol buster, evolocumab, putting it ahead in the race to get the first PCSK9 inhibitor to market. The Phase III clinical trial of evolocumab, an injectable monoclonal antibody that inhibits PCSK9 (proprotein convertase subtilisin kexin type 9), met the primary endpoint of percent reduction from
Mid-stage clinical data for Roche’s asthma drug, lebrikizumab, has demonstrated that the drug significantly reduced attacks in patients with severe uncontrolled asthma. Roche presented the Phase IIb clinical data at the American Academy of Allergy, Asthma and Immunology meeting in San Diego yesterday. The data from the clinical trials showed that asthma attacks were reduced
Eli Lilly has announced the results of their head-to-head clinical study which demonstrates that their investigational GLP-1 glucagon-like peptide 1 receptor agonist, dulaglutide, is just as effective as Novo Nordisk’s Victoza, the market-leader in the area. The pharmaceutical company revealed the positive top-line results of the sixth clinical trial in their AWARD programme, whereby once-weekly
Pfizer announced yesterday that Chantix/Champix (varenicline) has been shown to help smokers unable to quit ‘cold turkey’ kick their habit by slowly reducing the amount of cigarettes they smoke. The initial clinical study to assess the drug demonstrated that Chantix/Champix helped improve abstinence rates, in people wanting to reduce smoking prior to quitting.
An alliance of pharmaceutical and biotechnology industry associations, researchers and patient groups have asserted that the Council of the European Union needs to maintain the competitive timelines for assessment set out in the European Commission’s proposed regulation on clinical trials if they want to keep Europe at the front end of biopharmaceutical innovation. The alliance
Roche have posted positive clinical trial Phase II results for lampalizumab when treating age-related macular degeneration (AMD). The clinical trial demonstrated that patients with the dry form of AMD had a 20% reduction in geographic atrophy after 18 months’ treatment.
Payer demand for value indicators that can guide compensation conclusions are prompting top pharmaceutical companies to increasingly request input into clinical development from their health economics department, according to a new study. While clinical data is fundamental in driving reimbursement decisions, companies that only evaluate finished clinical trial data to determine a product’s economic benefit
GlaxoSmithKline and Johnson & Johnson (J&J) announced yesterday that they have started Phase III clinical trials of their investigational rheumatoid arthritis (RA) treatment, sirukumab. Johnson & Johnson’s Janssen Biologics unit in Ireland and GlaxoSmithKline have begun a Phase III development programme for sirukumab (otherwise known as CNTO 136), a human anti-interleukin (IL)-6 monoclonal antibody. The